Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

Jens Bedke,Axel S Merseburger,Yohann Loriot,Daniel Castellano,Ernest Choy,Ignacio Duran,Jonathan E Rosenberg,Daniel P Petrylak,Robert Dreicer,Jose L Perez-Gracia,Jean H Hoffman-Censits,Michiel S Van Der Heijden,Julie Pavlova,Lars Thiebach,Sabine de Ducla,Simon Fear,Thomas Powles,Cora N Sternberg

European Urology Focus（2021）

引用 5|浏览35

暂无评分

摘要

Patients with platinum-pretreated urothelial carcinoma achieving a partial response or stable disease on atezolizumab had good clinical outcomes. Tumour control was sustained in patients with stable disease. Partial response and stable disease are clinically meaningful outcomes meriting continuation of therapy.

查看译文

关键词

Atezolizumab,Immunotherapy,Partial response,Programmed cell death ligand 1,Stable disease,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要